Welcome to our dedicated page for CALLAN JMB SEC filings (Ticker: CJMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Callan JMB Inc. filings document the public-company record of a Nevada corporation operating in healthcare logistics, cold-chain fulfillment, emergency preparedness support and pharmaceutical supply-chain services. The company’s Form 8-K reports furnish operating results, business updates, Regulation FD investor materials, material agreements and amendments to common stock purchase arrangements.
Registration statements describe the company’s securities offering, business disclosures, capital structure and risk factors. Proxy materials cover annual-meeting procedures, stockholder voting matters and governance. Recent current reports also document Nasdaq continued-listing compliance matters, including disclosures related to the stockholders’ equity standard for The Nasdaq Capital Market.
CALLAN JMB INC. Chief Medical Officer and 10% owner David J. Croyle reported an indirect open-market purchase of 14,805 shares of Common Stock at $1.762 per share through a Rollover IRA on March 6, 2026. Following this transaction, his indirect holdings total 789,805 shares, making this a relatively small addition to an already substantial position.
Bard Associates, Inc. has filed an amended Schedule 13G reporting beneficial ownership of 245,682 shares of CALLAN JMB INC. common stock, representing 5.3% of the outstanding class. This reflects Bard’s status as a significant institutional holder of the company’s shares.
The event date for this ownership position is listed as 12/04/2025. Bard reports no sole voting or dispositive power over the stock, but has shared dispositive power over all 245,682 shares. It certifies the shares are held in the ordinary course of business and not to influence control of the issuer.
Callan JMB Inc. filed a current report to inform investors that it will begin using a new investor presentation starting January 28, 2026 at the DealFlow Discovery Conference. The same presentation may also be used later with potential investors, industry analysts and other audiences.
The investor presentation is available on the company’s website in the Investor Relations section and is attached as Exhibit 99.1. The company notes that this information is being furnished under Regulation FD and, unless specifically stated otherwise, will not be treated as “filed” for liability purposes under the securities laws.
Callan JMB Inc. director Gerald Dial reported buying common stock and receiving stock options. On December 30, 2025, he purchased 461 shares of Callan JMB common stock at $1.22 per share and 1,539 shares at $1.20 per share, bringing his directly held common stock to 2,000 shares.
Separately, on February 4, 2025, he was granted an option to buy 25,000 shares of common stock at an exercise price of $4.00 per share, expiring on February 4, 2035. According to the disclosure, this option was granted on the first day of the company’s initial public offering and will vest on the first anniversary of the IPO closing, on February 4, 2026.
Callan JMB Inc. insider Wayne D. Williams reported buying additional shares of the company’s common stock. On 12/16/2025, Williams acquired 5,000 shares of Callan JMB Inc. common stock in an open market purchase coded as “P” at a price of $1.73 per share, held indirectly through Health Hero America, LLC.
After this transaction, Williams beneficially owned 84,355 shares of common stock through Health Hero America, LLC and also held other direct and indirect positions, including 2,267,488 shares held directly and 25,625 shares held indirectly through Warehouse Asset Management, LLC. Williams serves as CEO, Chairman, President, director and a 10% owner of Callan JMB Inc.
Callan JMB Inc. CEO, chairman and president Wayne D. Williams, who is also a director and 10% owner, reported open-market purchases of the company’s common stock. On December 11, 2025 he bought 62 shares at $1.79 per share, and on December 12, 2025 he bought 4,926 shares at $1.75 per share, bringing his direct beneficial ownership to 2,267,488 shares. On December 15, 2025 he purchased 10,810 shares at $1.70 per share through Health Hero America, LLC, which then held 79,355 shares for him indirectly, alongside 25,625 shares held indirectly through Warehouse Asset Management, LLC.
Callan JMB Inc. CEO, Chairman and President Wayne D. Williams, who is also a director and 10% owner, reported insider purchases of the company’s common stock on 12/10/2025 and 12/11/2025. The transactions used code “P” for purchases.
Through Health Hero America, LLC, which he solely owns, he acquired 13,689 and 30,856 shares at $1.65 per share, bringing that entity’s beneficial holdings to 68,545 shares after the later trade. He also reports beneficial ownership of 2,262,500 shares directly and 25,625 shares indirectly through Warehouse Asset Management, LLC, in which he holds a 41% ownership interest.
Callan JMB Inc. is asking shareholders to vote at its 2025 virtual annual meeting on December 29, 2025. Investors will elect five directors, including CEO Wayne Williams and executives Eric Kash and independent nominees Mark Meller, Liberty Duke and Senator Gerald Dial, each to serve until the 2026 meeting. Shareholders are also being asked to ratify Rosenberg Rich Baker Berman, P.A. as the independent auditor for the year ending December 31, 2025.
The meeting will be held online only, with access using a Virtual Control Number, and shareholders of record at the close of business on November 24, 2025, may vote. As of that date, the company had 4,623,027 common shares outstanding, with Williams and Chief Medical Officer David Croyle together controlling a large majority. The proxy describes board independence, committee structure, related-party transactions and executive employment and incentive arrangements.
Callan JMB Inc. (CJMB) filed its Q3 2025 10‑Q reporting higher quarterly revenue but wider losses. Q3 revenue was $1,446,917 (vs. $1,435,376 a year ago), with gross profit of $493,307. Selling, general and administrative expenses rose to $2,372,465, driving an operating loss of $(1,879,158) and a net loss of $(2,731,341).
For the first nine months, revenue was $4,562,604 (vs. $5,211,665), and net loss expanded to $(5,373,327). Operating cash flow was $(3,887,737). Cash and cash equivalents were $2,789,744 at September 30, 2025. Governmental customers accounted for most sales, led by emergency preparedness at $973,921 in Q3.
The company completed an IPO in February, raising gross proceeds of about $5,776,000 (net ~$4,700,000), and established a $25,000,000 equity line of credit. Under the facility, ~123,208 shares were issued for net proceeds of ~$497,750, and a derivative liability of $624,041 was recorded. Shares outstanding were 4,623,027 as of September 30, 2025; as of November 14, 2025, 4,623,027 shares were issued and outstanding.
Callan JMB Inc. announced financial results for the third quarter ended September 30, 2025. The company furnished the full press release as Exhibit 99.1 to a Form 8-K and stated the information is “furnished” and not deemed “filed” under the Exchange Act, nor incorporated by reference unless specifically referenced. The company’s common stock trades on Nasdaq under the symbol CJMB.